An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
Trial details
- Registry ID
- NCT05022901
- Drugs studied
- Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS)
TrialRedline tracks 4 clinical trials sponsored by Delcath Systems Inc.: 2 Phase 3, 2 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular MelanomaNCT05022901 | Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS) | Active not recruiting | 2024-03-01Estimated |
| Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular MelanomaNCT02678572 | Melphalan/HDS | Completed | 2023-05-18Actual |
Names as written in the registry records.
NCT02678572 · Delcath Systems Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Objective Response Rate (ORR) as determined by Independent Central Review Committee. After: Measure: Objective Response Rate (ORR) as Determined by Independent Central Review Committee..
Before: Not yet recruiting. After: Recruiting.